The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders

Frontiers in Neurology

Volumn 6, Issue MAR, 2015, Pages

  Dobryakova, Ekaterina ^a,b   Genova, Helen M ^a,b   DeLuca, John ^a,b   Wylie, Glenn R ^a,b,c  

^a KESSLER FOUNDATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Dopamine; Fatigue; Mesocorticolimbic system; Methylphenidate; MRI

Indexed keywords

ACETYLCARNITINE; AMANTADINE; BETA INTERFERON; BETA1A INTERFERON; DOPAMINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 1; INTERLEUKIN 6; METHYLPHENIDATE; MODAFINIL; NEUROTRANSMITTER; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CHRONIC FATIGUE SYNDROME; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG EFFICACY; FATIGUE; HUMAN; IMMUNE SYSTEM; MULTIPLE SCLEROSIS; NARCOLEPSY; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; REVIEW; SOMNOLENCE; TRAUMATIC BRAIN INJURY;

EID: 84926504978     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00052     Document Type: Review

References (93)

1. Walker LAS, Berard JA, Berrigan LI, Rees LM, Freedman MS. Detecting cognitive fatigue in multiple sclerosis: method matters. J Neurol Sci (2012) 316:86-92. doi: 10.1016/j.jns.2012.01.021
2. Zifko UA. Management of fatigue in patients with multiple sclerosis. Drugs (2004) 64:1295-304. doi:10.2165/00003495-200464120-00003
3. Cantor JB, Gordon W, Gumber S. What is post TBI fatigue? NeuroRehabilitation (2013) 32:875-83. doi:10.3233/NRE-130912
4. Friedman JH, Abrantes A, Sweet LH. Fatigue in Parkinson's disease. Expert Opin Pharmacother (2011) 12:1999-2007. doi:10.1517/14656566.2011.587120
5. Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res (2010) 19:1419-27. doi:10.1007/s11136-010-9757-7
6. Jong E, Oudhoff LA, Epskamp C, Wagener MN, van Duijn M, Fischer S, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS (2010) 24:1387-405. doi:10.1097/QAD.0b013e328339d004
7. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med (1994) 121:953-9. doi:10.7326/0003-4819-121-12-199412150-00009
8. Harrington ME. Neurobiological studies of fatigue. Prog Neurobiol (2012) 99:93-105. doi:10.1016/j.pneurobio.2012.07.004
9. Chaudhuri A, Behan PO. Fatigue and basal ganglia. J Neurol Sci (2000) 179:34-42. doi:10.1016/S0022-510X(00)00411-1
10. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev (2000) 24:125-32. doi:10.1016/S0149-7634(99)00063-9
11. Cosentino M, Marino F. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? J Neuroimmune Pharmacol (2013) 8:163-79. doi:10.1007/s11481-012-9410-z
12. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol (2002) 67:53-83. doi:10.1016/S0301-0082(02)00011-4
13. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol (2004) 74:1-57. doi:10.1016/j.pneurobio.2004.05.006
14. Dalley JW, Roiser JP. Dopamine, serotonin and impulsivity. Neuroscience (2012) 215:42-58. doi:10.1016/j.neuroscience.2012.03.065
15. Haber SN, Fudge JL, McFarland NR. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci (2000) 20:2369-82.
16. Haber SN, Kim KS, Mailly P, Calzavara R. Reward-related cortical inputs define a large striatal region in primates that interface with associative cortical connections, providing a substrate for incentive-based learning. J Neurosci (2006) 26:8368-76. doi:10.1523/JNEUROSCI.0271-06.2006
17. Basu S, Dasgupta PS. Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol (2000) 102:113-24. doi:10.1016/S0165-5728(99)00176-9
18. Pacheco R, Contreras F, Zouali M. The dopaminergic system in autoimmune diseases. Front Immunol (2014) 5:117. doi:10.3389/fimmu.2014.00117
19. Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol (2001) 63:241-320. doi:10.1016/S0301-0082(00)00033-2
20. Hollerman JR, Tremblay L, Schultz W. Influence of reward expectation on behavior-related neuronal activity in primate striatum. J Neurophysiol (1998) 80:947-63.
21. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol (1998) 80:1-27.
22. Stefani MR, Moghaddam B. Rule learning and reward contingency are associated with dissociable patterns of dopamine activation in the rat prefrontal cortex, nucleus accumbens, and dorsal striatum. J Neurosci (2006) 26:8810-8. doi:10.1523/JNEUROSCI.1656-06.2006
23. Salamone JD, Correa M, Mingote S, Weber SM. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther (2003) 305:1-8. doi:10.1124/jpet.102.035063
24. Assadi SM, Yucel M, Pantelis C. Dopamine modulates neural networks involved in effort-based decision-making. Neurosci Biobehav Rev (2009) 33:383-93. doi:10.1016/j.neubiorev.2008.10.010
25. Cools R, D'Esposito M. Inverted-U shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry (2011) 69:e113-25. doi:10.1016/j.biopsych.2011.03.028
26. Takahashi H, Yamada M, Suhara T. Functional significance of central D1 receptors in cognition: beyond working memory. J Cereb Blood Flow Metab (2012) 32:1248-58. doi:10.1038/jcbfm.2011.194
27. Klanker M, Feenstra M, Denys D. Dopaminergic control of cognitive flexibility in humans and animals. Front Neurosci (2013) 7:201. doi:10.3389/fnins.2013.00201
28. Dobryakova E, DeLuca J, Genova HM, Wylie GR. Neural correlates of cognitive fatigue: cortico-striatal circuitry and effort-reward imbalance. J Int Neuropsych Soc (2013) 19(8):849-53. doi:10.1017/S1355617713000684
29. Pardini M, Bonzano L, Mancardi GL, Roccatagliata L. Frontal networks play a role in fatigue perception in multiple sclerosis. Behav Neurosci (2010) 124:329-36. doi:10.1037/a0019585
30. Pardini M, Krueger F, Raymont V, Grafman J. Ventromedial prefrontal cortex modulates fatigue after penetrating traumatic brain injury. Neurology (2010) 74:749-54. doi:10.1212/WNL.0b013e3181d25b6b
31. Genova HM, Rajagopalan V, Deluca J, Das A, Binder A, Arjunan A, et al. Examination of cognitive fatigue in multiple sclerosis using functional magnetic resonance imaging and diffusion tensor imaging. PLoS One (2013) 8:e78811. doi:10.1371/journal.pone.0078811
32. Koch K, Wagner G, Schachtzabel C, Schultz CC, Güllmar D, Reichenbach JR, et al. Association between white matter fiber structure and reward-related reactivity of the ventral striatum. Hum Brain Mapp (2013) 35(4):1469-76. doi:10.1002/hbm.22284
33. Tang WK, Chen YK, Mok V, Chu WCW, Ungvari GS, Ahuja AT, et al. Acute basal ganglia infarcts in poststroke fatigue: an MRI study. J Neurol (2010) 257:178-82. doi:10.1007/s00415-009-5284-2
34. Tang WK, Liang HJ, Chen YK, Chu WCW, Abrigo J, Mok VCT, et al. Poststroke fatigue is associated with caudate infarcts. J Neurol Sci (2013) 15:131-5. doi:10.1016/j.jns.2012.10.022
35. Téllez N, Alonso J, Río J, Tintoré M, Nos C, Montalban X, et al. The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology (2008) 50:17-23. doi:10.1007/s00234-007-0304-3
36. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 48:1566-71. doi:10.1212/WNL.48.6.1566
37. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 46:1121-3. doi:10.1001/archneur.1989.00520460115022
38. Esposito F, Otto T, Zijlstra FRH, Goebel R. Spatially distributed effects of mental exhaustion on resting-state FMRI networks. PloS One (2014) 9(4):e94222. doi:10.1371/journal.pone.0094222
39. Engström M, Flensner G, Landtblom A-M, Ek A-C, Karlsson T. Thalamo-striato-cortical determinants to fatigue in multiple sclerosis. Brain Behav (2013) 3:715-28. doi:10.1002/brb3.181
40. Finke C, Schlichting J, Papazoglou S, Scheel M, Freing A, Soemmer C, et al. Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue. Mult Scler (2014). doi:10.1177/1352458514555784
41. Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med (2006) 119:e23-30. doi:10.1016/j.amjmed.2005.07.047
42. Johansson B, Wentzel A, Andrell P, Odenstedt J, Mannheimer C, Ronnback L. Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain. Brain Inj (2014) 28:304-10. doi:10.3109/02699052.2013.865267
43. Wallace DL, Vytlacil JJ, Nomura EM, Gibbs SEB, D'Esposito M. The dopamine agonist bromocriptine differentially affects fronto-striatal functional connectivity during working memory. Front Hum Neurosci (2011) 5:32. doi:10.3389/fnhum.2011.00032
44. Konova AB, Moeller SJ, Tomasi D, Volkow ND, Goldstein RZ. Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. JAMA Psychiatry (2013) 70:857-68. doi:10.1001/jamapsychiatry.2013.1129
45. Mueller S, Costa A, Keeser D, Pogarell O, Berman A, Coates U, et al. The effects of methylphenidate on whole brain intrinsic functional connectivity. Hum Brain Mapp (2014) 35(11):5379-88. doi:10.1002/hbm.22557
46. Wylie GR, Javitt DC, Foxe JJ. Jumping the gun: is effective preparation contingent upon anticipatory activation in task-relevant neural circuitry? Cereb Cortex (2006) 16:394-404. doi:10.1093/cercor/bhi118
47. Wylie GR, Sumowski JF, Murray M. Are there control processes, and (if so) can they be studied? Psychol Res (2011) 75(6):535-43. doi:10.1007/s00426-011-0354-3
48. Weaver SM, Foxe JJ, Shpaner M, Wylie GR. You can't always get what you want: the influence of unexpected task constraint on voluntary task switching. Q J Exp Psychol (Hove) (2014) 67(11):2247-59. doi:10.1080/17470218.2014.917115
49. Miller AH, Jones JF, Drake DF, Tian H, Unger ER, Pagnoni G. Decreased basal ganglia activation in subjects with chronic fatigue syndrome: association with symptoms of fatigue. PLoS One (2014) 9:e98156. doi:10.1371/journal.pone.0098156
50. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology (1995) 45:1956-61. doi:10.1212/WNL.45.11.1956
51. Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev (2007) 1:CD002818. doi:10.1002/14651858.CD002818.pub2
52. Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 64:1139-43. doi:10.1212/01.WNL.0000158272.27070.6A
53. Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadine, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis-result of a pilot randomized, blind study. Clin Neurol Neurosurg (2013) 1155:S86-9. doi:10.1016/j.clineuro.2013.09.029
54. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs (2008) 68:1803-39. doi:10.2165/00003495-200868130-00003
55. Kaminska M, Kimoff RJ, Schwartzman K, Trojan DA. Sleep disorders and fatigue in multiple sclerosis: evidence for association and interaction. J Neurol Sci (2011) 302:7-13. doi:10.1016/j.jns.2010.12.008
56. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry (2002) 72:179-83. doi:10.1136/jnnp.72.2.179
57. Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One (2013) 8:e81802. doi:10.1371/journal.pone.0081802
58. Zaffaroni M, Marino F, Bombelli R, Rasini E, Monti M, Ferrari M, et al. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol (2008) 214:315-21. doi:10.1016/j.expneurol.2008.08.015
59. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci (2001) 21:RC121.
60. Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care (2012) 29:483-90. doi:10.1177/1049909111427029
61. Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord (2007) 22:2070-6. doi:10.1002/mds.21656
62. Roth AJ, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer (2010) 116:5102-10. doi:10.1002/cncr.25424
63. Gibbs SEB, D'Esposito M. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn Affect Behav Neurosci (2005) 5:212-21. doi:10.3758/CABN.5.2.212
64. Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci (2009) 276:38-40. doi:10.1016/j.jns.2008.08.025
65. Vytlacil J, Kayser A, Miyakawa A, D'Esposito M. An approach for identifying brainstem dopaminergic pathways using resting state functional MRI. PLoS One (2014) 9:e87109. doi:10.1371/journal.pone.0087109
66. Kerr CW, Drake J, Milch RA, Brazeau DA, Skretny JA, Brazeau GA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage (2012) 43:68-77. doi:10.1016/j.jpainsymman.2011.03.026
67. Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: north central cancer treatment group NCCTG-N05C7 trial. J Clin Oncol (2010) 28:3673-9. doi:10.1200/JCO.2010.28.1444
68. Yennurajalingam S, Palmer JL, Chacko R, Bruera E. Factors associated with response to methylphenidate in advanced cancer patients. Oncologist (2011) 16:246-53. doi:10.1634/theoncologist.2010-0214
69. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med (2001) 161:411-20. doi:10.1001/archinte.161.3.411
70. Cosentino M, Zaffaroni M, Ferrari M, Marino F, Bombelli R, Rasini E, et al. Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. J Neuroimmunol (2005) 162:112-21. doi:10.1016/j.jneuroim.2005.01.019
71. González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, et al. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease. J Immunol (2013) 190:5048-56. doi:10.4049/jimmunol.1203121
72. Dijkstra CD, van der Voort ER, De Groot CJA, Huitinga I, Uitdehaag BMJ, Polman CH, et al. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology (1994) 19:135-42. doi:10.1016/0306-4530(94)90003-5
73. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurol (2010) 74(Suppl 1):S17-24. doi:10.1212/WNL.0b013e3181c97d99
74. Giorelli M, Livrea P, Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J Interferon Cytokine Res (2005) 25:395-406. doi:10.1089/jir.2005.25.395
75. Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, et al. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-ß therapy. Neuroimmunomodulation (2012) 19:283-92. doi:10.1159/000336981
76. Melanson M, Grossberndt A, Klowak M, Leong C, Frost EE, Prout M, et al. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon ß. Int J Neurosci (2010) 120:631-40. doi:10.3109/00207454.2010.511732
77. Parent M, Wallman M-J, Gagnon D, Parent A. Serotonin innervation of basal ganglia in monkeys and humans. J Chem Neuroanat (2011) 41:256-65. doi:10.1016/j.jchemneu.2011.04.005
78. Mathur BN, Lovinger DM. Serotonergic action on dorsal striatal function. Parkinsonism Relat Disord (2012) 1:129-31. doi:10.1016/S1353-8020(11)70040-2
79. De Deurwaerdère P, Lagière M, Bosc M, Navailles S. Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology. Exp Brain Res (2013) 230:477-511. doi:10.1007/s00221-013-3508-2
80. Meeusen R, Watson P, Hasegawa H, Roelands B, Piacentini MF. The serotonin hypothesis and beyond. Sports Med (2006) 36:881-909. doi:10.2165/00007256-200636100-00006
81. Meeusen R, Roelands B. Central fatigue and neurotransmitters, can thermoregulation be manipulated? Scand J Med Sci Sports (2010) 20(Suppl 3):19-28. doi:10.1111/j.1600-0838.2010.01205.x
82. Yamamoto S, Ouchi Y, Onoe H, Yoshikawa E, Tsukada H, Takahashi H, et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport (2004) 15:2571-4. doi:10.1097/00001756-200412030-00002
83. Hesse S, Moeller F, Petroff D, Lobsien D, Luthardt J, Regenthal R, et al. Altered serotonin transporter availability in patients with multiple sclerosis. Eur J Nucl Med Mol Imaging (2014) 41:827-35. doi:10.1007/s00259-013-2636-z
84. The GKH, Verkes RJ, Fekkes D, Bleijenberg G, van der Meer JWM, Buitelaar JK. Tryptophan depletion in chronic fatigue syndrome, a pilot cross-over study. BMC Res Notes (2014) 7:650. doi:10.1186/1756-0500-7-650
85. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain (2010) 133:3434-43. doi:10.1093/brain/awq268
86. Di Giovanni G, Esposito E, Di Matteo V. Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther (2010) 16:179-94. doi:10.1111/j.1755-5949.2010.00135.x
87. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol (2012) 33:315-27. doi:10.1016/j.yfrne.2012.09.003
88. Smith AP. Twenty-five years of research on the behavioural malaise associated with influenza and the common cold. Psychoneuroendocrinology (2013) 38:744-51. doi:10.1016/j.psyneuen.2012.09.002
89. Dantzer R, Heijnen CJ, Kavelaars A, Laye S, Capuron L. The neuroimmune basis of fatigue. Trends Neurosci (2014) 37:39-46. doi:10.1016/j.tins.2013.10.003
90. Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, et al. Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology (Berl) (2014) 231:727-36. doi:10.1007/s00213-013-3285-4
91. Salamone JD, Correa M, Nunes EJ, Randall PA, Pardo M. The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond. J Exp Anal Behav (2012) 97:125-46. doi:10.1901/jeab.2012.97-125
92. Ishiwari K, Weber SM, Mingote S, Correa M, Salamone JD. Accumbens dopamine and the regulation of effort in food-seeking behavior: modulation of work output by different ratio or force requirements. Behav Brain Res (2004) 151:83-91. doi:10.1016/j.bbr.2003.08.007
93. Stolyarova A, Thompson AB, Barrientos RM, Izquierdo A. Reductions in frontocortical cytokine levels are associated with long-lasting alterations in reward valuation after methamphetamine. Neuropsychopharmacology (2014). doi:10.1038/npp.2014.309